Autoimmune manifestations following COVID-19 infection in two individuals with primary immunodeficiency

Publication: LymphoSign Journal
10 July 2024

Abstract

Background: Due to widespread vaccination efforts worldwide, the mortality rates linked to COVID-19 have been decreasing. Nevertheless, there persists a notable level of morbidity, marked by increased occurrences of post-COVID-19 conditions. This includes the development of new autoimmune and inflammatory diseases in individuals who have recovered from COVID-19. A more severe progression of COVID-19 has been correlated with an increased probability of newly diagnosed autoimmune disease, and among individuals with pre-existing autoimmune conditions, COVID-19 increased the risk of developing another autoimmune disease.
Methods: Our patients’ medical records were analyzed retrospectively, including their medical history.
Results: We present two cases of primary immunodeficiency patients. One of them experienced the onset of new autoimmune symptoms, while the other had a worsening of her autoimmune condition following COVID-19 infection.
Conclusion: Recognizing the potential connection between COVID-19 and autoimmune conditions is crucial for identifying symptoms promptly in primary immunodeficiency patients and ensuring timely treatment. Further research is required to comprehensively grasp the relationship between COVID-19 and the development of autoimmunity in this particular patient group.
Statement of novelty: In this paper, we present a novel exploration into the emergence of autoimmune manifestations in primary immunodeficiency patients subsequent to COVID-19 infection, through an analysis of two distinct case reports.

Get full access to this article

View all available purchase options and get full access to this article.

REFERENCES

Al-Mayouf S.M., Naji H., Alismail K., Alazami A.M., Sheikh F., Conca W., and Al-Mousa H. 2017. Evolving spectrum of LRBA deficiency-associated chronic arthritis: Is there a causative role in juvenile idiopathic arthritis? Clin. Exp. Rheumatol. 35: 327–329.
Chang R., Yen-Ting Chen T., Wang S.-I., Hung Y.-M., Chen H.-Y., and Wei C.C.J. 2023. Risk of autoimmune diseases in patients with COVID-19: A retrospective cohort study. eClinicalMedicine, 56: 101783.
Costagliola G., Cappelli S., and Consolini R. 2021. Autoimmunity in primary immunodeficiency disorders: an updated review on pathogenic and clinical implications. J. Clin. Med. 10: 4729.
Dorjbal B., Stinson J.R., Ma C.A., Weinreich M.A., Miraghazadeh B., Hartberger J.M., Frey-Jakobs S., Weidinger S., Moebus L., Franke A., Schäffer A.A., Bulashevska A., Fuchs S., Ehl S., Limaye S., Arkwright P.D., Briggs T.A., Langley C., Bethune C., Whyte A.F., Alachkar H., Nejentsev S., DiMaggio T., Nelson C.G., Stone K.D., Nason M., Brittain E.H., Oler A.J., Veltri D.P., Leahy T.R., Conlon N., Poli M.C., Borzutzky A., Cohen J.I., Davis J., Lambert M.P., Romberg N., Sullivan K.E., Paris K., Freeman A.F., Lucas L., Chandrakasan S., Savic S., Hambleton S., Patel S.Y., Jordan M.B., Theos A., Lebensburger J., Atkinson T.P., Torgerson T.R., Chinn I.K., Milner J.D., Grimbacher B., Cook M.C., and Snow A.L. 2019. Hypomorphic caspase activation and recruitment domain 11 (CARD11) mutations associated with diverse immunologic phenotypes with or without atopic disease. J. Allergy Clin. Immunol. 143: 1482–1495.
Esenboga S., Ocak M., Akarsu A., Bildik H.N., Cagdas D., Iskit A.T., and Tezcan I. 2021. COVID-19 in patients with primary immunodeficiency. J. Clin. Immunol. 41: 1515–1522.
Garmendia J.V., García A.H., De Sanctis C.V., Hajdúch M., and De Sanctis J.B. 2022. Autoimmunity and immunodeficiency in Severe SARS-CoV-2 infection and prolonged COVID-19. Curr. Iss. Mol. Biol. 45: 33–50.
Gracia-Ramos A.E., Martin-Nares E., and Hernández-Molina G. 2021. New onset of autoimmune diseases following COVID-19 diagnosis. Cells, 10: 3592.
He M., Wong A., Sutton K., Gondim M.J.B., and Samson C. 2023. Very-early onset chronic active colitis with heterozygous variants in LRBA1 and CARD11, a case of “Immune TOR-Opathies.” Fetal Pediatr. Pathol. 42: 297–306.
Kostel Bal S., Haskologlu S., Serwas N.K., Islamoglu C., Aytekin C., Kendirli T., Kuloglu Z., Yavuz G., Dalgic B., Siklar Z., Kansu A., Ensari A., Boztug K., Dogu F., and Ikinciogullari A. 2017. Multiple presentations of LRBA deficiency: a single-center experience. J. Clin. Immunol. 37: 790–800.
Lu H.Y., Bauman B.M., Arjunaraja S., Dorjbal B., Milner J.D., Snow A.L., and Turvey S.E. 2018. The CBM-opathies—a rapidly expanding spectrum of human inborn errors of immunity caused by mutations in the CARD11-BCL10-MALT1 complex. Front. Immunol. 9: 2078.
Peng K., Li X., Yang D., Chan S.C.W., Zhou J., Wan E.Y.F., Chui C.S.L., Lai F.T.T., Wong C.K.H., Chan E.W.Y., Leung W.K., Lau C.S., and Wong I.C.K. 2023. Risk of autoimmune diseases following COVID-19 and the potential protective effect from vaccination: a population-based cohort study. eClinicalMedicine, 63: 102154.
Rasouli S. E., Sharifinejad N., Fallahi M., Hashemi Moghaddam S. A., Jamee M., Rekabi M., Daneshmand Z., Mahdaviani S. A., and Velayati A. A. 2022. Joint Involvement in Patients with LPS-Responsive and Beige-Like Anchor Protein (LRBA) Deficiency: A Case Report and Literature Review. Immunology and Genetics Journal.
Semo Oz R. and Tesher S. 2019. Arthritis in children with LRBA deficiency – case report and literature review. Pediatr. Rheumatol. 17: 82.
Sharma C. and Bayry J. 2023. High risk of autoimmune diseases after COVID-19. Nature Rev. Rheumatol. 19: 399–400.
Tesch, F., Ehm, F., Vivirito, A., Wende, D., Batram, M., Loser, F., Menzer, S., Jacob, J., Roessler, M., Seifert, M., Kind, B., König, C., Schulte, C., Buschmann, T., Hertle, D., Ballesteros, P., Baßler, S., Bertele, B., Bitterer, T., Riederer, C., Sobik, F., Reitzle, L., Scheidt-Nave, C., and Schmitt, J. 2023. Incident autoimmune diseases in association with a SARS-CoV-2 infection: a matched cohort study. Clin. Rheumatol. 42: 2905. 37335408.
Urdinez L., Erra L., Palma A.M., Mercogliano M.F., Fernandez J.B., Prieto E., Goris V., Bernasconi A., Sanz M., Villa M., Bouso C., Caputi L., Quesada B., Solis D., Aguirre Bruzzo A., Katsicas M.M., Galluzzo L., Weyersberg C., Bocian M., Bujan M.M., Oleastro M., Almejun M.B., and Danielian S. 2022. Expanding spectrum, intrafamilial diversity, and therapeutic challenges from 15 patients with heterozygous CARD11-associated diseases: a single center experience. Front. Immunol. 13: 1020927.

Information & Authors

Information

Published In

cover image LymphoSign Journal
LymphoSign Journal
Volume 11Number 2June 2024
Pages: 26 - 31

History

Received: 4 May 2024
Accepted: 21 May 2024
Accepted manuscript online: 27 May 2024
Version of record online: 10 July 2024

Authors

Affiliations

Azhar Al Shaqaq [email protected]
Division of Immunology & Allergy, Department of Pediatrics, Hospital for Sick Children and University of Toronto, Toronto, ON
Abdulrahman Al Ghamdi
Division of Immunology & Allergy, Department of Pediatrics, Hospital for Sick Children and University of Toronto, Toronto, ON

Metrics & Citations

Metrics

Other Metrics

Citations

Cite As

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

There are no citations for this item

View Options

Get Access

Login options

Check if you access through your login credentials or your institution to get full access on this article.

Subscribe

Click on the button below to subscribe to LymphoSign Journal

Purchase options

Purchase this article to get full access to it.

Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

View options

PDF

View PDF

Full Text

View Full Text

Media

Media

Other

Tables

Share Options

Share

Share the article link

Share on social media